



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: **Warren, et al.**

Examiner: **Chernyshev, O.**

Serial No.: **09/813,463**

Group Art Unit: **1653**

Filed: **March 20, 2001**

Docket: **098810/027 8740**

For: **PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE  
ADMINISTRATION OF MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE  
SCLEROSIS PATIENTS**

**STATEMENT UNDER 37 C.F.R. § 1.821 (f) and (g)**

Commissioner of Patents  
Washington, D.C. 20231

Sir:


In connection with the Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. The paper copy of the Sequence Listing, submitted in accordance with 37 CFR 1.825(b), is the same as the computer readable copy of the Sequence Listing; and
2. The content of the Sequence Listing information recorded in computer readable form is identical to the paper copy of the Sequence, submitted in accordance with 37 C.F.R. §1.825(a), does not include any new matter.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: 12-1-03

  
Robert M. Bedgood  
Reg. No. 43,488

PILLSBURY WINTHROP LLP  
11682 EL CAMINO REAL, SUITE 200  
SAN DIEGO, CA 92130

RECEIVED  
DEC 12 2003  
TECHNOLOGY CENTER 2800

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8**

I hereby certify that this correspondence (along with any paper referred to as being attached or enclosed) is being mailed with the United States Postal Services on the date shown below in an envelope addressed to the United States Patent and Trademark Office, Attn: Box Sequence, P.O. Box 1450, Mail Stop Sequence Listing, Alexandria, VA 22313-1450

Dated: 12/1/03

By: Pete Munoz